Kindred Biosciences Announces Global Sponsorship of International Society of Equine Locomotion Pathology
San Francisco, CA (March 7, 2017) Kindred Biosciences, Inc. (NASDAQ: KIN), a biopharmaceutical company focused on saving and improving the lives of pets, is proud to announce its partnership with the International Society of Equine Locomotion Pathology (ISELP) by joining their team of Global Sponsors starting in 2017. The partnership with ISELP is part of an initiative by KindredBio to support the education of veterinarians and veterinary students, and to promote the growth and advancement of the equine industry. ISELP is an advanced education program for equine veterinarians to learn the most advanced techniques in diagnostics and treatments for the performance horse.
Kent Allen, DVM, Vice President & Executive Director of ISELP said, “It is a great pleasure to welcome KindredBio to the ISELP family of Global Sponsors. I am thrilled that we have this opportunity. KindredBio fits into our ISELP model because of their leading-edge technology and commitment to excellence in equine healthcare. We look forward to many productive years of collaboration and networking.”
KindredBio looks forward to announcing its global sponsorship of the ISELP Student Education Program starting in 2017, which will be made to ISELP members attending the 3-Day meeting in Irving, Texas, March 7-11, 2017.
“The commitment to supporting continuing education of this caliber for equine veterinarians and students is at the core of our culture at KindredBio. We are honored to be partnered with ISELP, an organization at the apex of equine education,” said Denise Bevers, Co-Founder and Chief Operating Officer of KindredBio.
About Kindred Biosciences
Kindred Biosciences is a development-stage biopharmaceutical company focused on saving and improving the lives of pets. Its mission is to bring to pets the same kinds of safe and effective medicines that human family members enjoy. The Company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats and horses. The Company has a deep pipeline of novel drugs and biologics in development across many therapeutic classes.
“Continuing education of equine practitioners for a better management of patients”
Formed in the United States, under the direction of Dr. Jean-Marie Denoix, The International Society of Equine Locomotor Pathology (ISELP) will focus on the problem of lameness in the equine athlete. The goal of ISELP is to provide contemporary knowledge and techniques in the continually evolving field of equine locomotor analysis to better prepare the equine clinician to understand and manage lameness conditions in the equine athlete. Founded in 2006, ISELP is rapidly growing and currently has members on all five continents.